BPC-157 and TB-500 are the two most-discussed compounds in tissue-repair research, and they are constantly grouped together — often to the point of being treated as interchangeable. They are not. They act through entirely unrelated mechanisms, and neither is a weaker version of the other. The reason the literature studies them together is precisely that their mechanisms don’t overlap.
BPC-157 vs TB-500 at a Glance
| BPC-157 | TB-500 | |
|---|---|---|
| Full name | Body Protection Compound 157 | Thymosin Beta-4 |
| What it is | Fragment of a gastric protein | Full-length protein |
| Length | 15 amino acids | 43 amino acids |
| Molecular weight | 1419.55 | 4963.44 |
| CAS | 137525-51-0 | 77591-33-4 |
| Primary mechanism | VEGF angiogenesis · nitric oxide · prostaglandin signaling | Actin sequestration · cell migration |
| What it does, in one line | Builds the vascular supply to a repair site | Gets repair cells to the site |
| Most-studied models | Tendon, gut, bone, CNS | Wound healing, cardiac, corneal |
| Origin | Human gastric juice | Present in nearly every human cell |
| Human trial data | Effectively none, for either | |
| Approved anywhere? | No | |
| Controlled substance in Canada? | No | |
Before Comparing Them: What “TB-500” Actually Refers To
This has to come first, because most comparisons of these two compounds are comparing the wrong molecule.
The name “TB-500” originally referred to a seven-amino-acid fragment — the sequence LKKTETQ, the actin-binding domain of Thymosin Beta-4, molecular weight roughly 878.
But almost everything sold in the research market as “TB-500” is not that fragment. It is full-length Thymosin Beta-4 — the complete 43-amino-acid protein, molecular weight 4963. Different molecule. More than five times the mass. Same name.
CompoundPlug supplies full-length Thymosin Beta-4, and states so, with the molecular weight and full sequence published on the product page. Most vendors don’t distinguish. That matters for anyone calculating molar concentration, or comparing a vial against a published study — a calculation performed against the wrong molecular weight is out by a factor of five.
Everything below refers to full-length Thymosin Beta-4.
The Mechanisms: Vascular Supply vs Cell Migration
BPC-157 — angiogenesis and signaling
BPC-157 is a 15-amino-acid fragment derived from body protection compound, a protein identified in human gastric juice. Its activity in research models runs through several pathways at once: VEGF-mediated angiogenesis (new blood vessel formation), the nitric oxide system, and prostaglandin signaling.
The angiogenesis arm is the most-cited. Hsieh and colleagues (2017) reported that BPC-157 engages VEGFR2 signaling in a VEGF-independent manner — driving endothelial proliferation and tube formation directly. The hypothesis in the literature is that BPC-157 supports repair by improving the vascular supply to damaged tissue.
Chang and colleagues (2011) identified a second mechanism in tendon: fibroblast migration via the FAK-paxillin pathway.
TB-500 — actin sequestration
Thymosin Beta-4’s mechanism is completely different, and it is elegant.
Actin is the protein cells use to move. It exists in two states: G-actin (free monomers) and F-actin (polymerised filaments). To crawl toward a wound, a cell must build filaments at its leading edge and dismantle them behind — which requires a large pool of free G-actin monomers to draw from.
Tβ4 is the protein that maintains that pool. It binds G-actin and holds it in reserve, unpolymerised and available. It is the primary regulator of unpolymerised actin in mammalian cells, and it is present at concentrations of 0.4 to 0.8 millimolar in most cell types — one of the most abundant proteins there is.
Cells with access to a larger free-actin pool migrate faster. And tissue repair is fundamentally a migration problem: fibroblasts, endothelial cells, and epithelial cells all have to physically reach a damaged site before anything can be rebuilt.
Why this makes them complementary rather than competing
They operate on different stages of the same process.
BPC-157 builds the infrastructure — the vascular supply that a repair site needs in order to be supplied with anything at all. TB-500 moves the cells in.
Neither substitutes for the other, and this is why the literature examines them together as often as it examines them separately. It is also why CompoundPlug supplies them as a blend as well as individually.
The Research Base Compared
BPC-157
An unusually broad preclinical literature for a compound that has never completed a clinical trial. Anchored by the Zagreb group under Predrag Sikiric (Sikiric et al., 2011), with independent replication on tendon and bone models — Chang et al. (2011) at Chang Gung University, and Krivic et al. (2006) on tendon-to-bone healing. Models span tendon and ligament, gastric mucosa, bone, cardiovascular, and CNS.
TB-500 / Thymosin Beta-4
Research derives from the broader Tβ4 literature. Philp and colleagues (2003) reported accelerated dermal wound repair in impaired-healing models — and notably tested both full-length Tβ4 and a synthetic peptide containing the actin-binding domain, which is one of the few studies that distinguishes them. Hinkel and colleagues (2008) examined Tβ4 as a paracrine factor in a porcine myocardial infarction model.
What they have in common, and it is the most important fact here
The human research base for both compounds is effectively empty. Neither has completed clinical development. Neither has meaningful published human pharmacokinetic data. The preclinical record is deep for BPC-157 and moderate for TB-500; the human record, for both, is essentially absent.
Reported Effects and Safety
BPC-157 — preclinical models report accelerated fibroblast migration and increased growth-factor expression in tendon models, effects on gastric mucosal integrity, angiogenesis via VEGF signaling, and effects on bone healing. Adverse findings in the preclinical record are limited, though the research base is small. When the FDA restricted BPC-157 for pharmacy compounding in 2023, it cited potential immunogenicity, manufacturing impurity risk, and the absence of human safety data. That restriction was lifted in 2026.
TB-500 — models report wound closure, cardiomyocyte migration and survival after ischemic injury, corneal epithelial repair, and endothelial migration. One mechanistic concern appears in the literature and is worth stating: cell migration is not selectively beneficial. A mechanism that helps repair cells move faster does not distinguish between repair cells and other cells. TB-500 was also on the FDA’s Category 2 list from 2023; that restriction was lifted in 2026.
Neither compound has long-term human safety data. Effects reported in animal models do not translate reliably to humans.
Regulatory Status in Canada
Neither BPC-157 nor TB-500 is an authorized health product in Canada. Neither carries a DIN or NPN. Neither has been reviewed by Health Canada for human use.
Neither is a controlled substance under the Controlled Drugs and Substances Act.
CompoundPlug supplies both strictly as research chemicals for in-vitro and in-vivo laboratory research. See Research Use Only.
In Summary
BPC-157 acts on vascular and signaling pathways. TB-500 acts on cell migration through actin sequestration. They are not competing versions of the same compound — they are studied in different parts of the same process, which is why the literature examines them together as often as separately.
And before comparing them at all: know which TB-500 is in the vial. Most vendors won’t say.
- BPC-157 — 10mg. MW 1419.55, sequence published.
- TB-500 — 10mg. Full-length Thymosin Beta-4, MW 4963.44, sequence published.
- BPC-157 + TB-500 blend — both compounds, one vial.
- GLOW blend · KLOW blend — multi-mechanism repair blends.
- Healing Peptides — the full category.
Frequently Asked Questions
What is the difference between BPC-157 and TB-500?
Entirely different mechanisms. BPC-157 acts through VEGF-mediated angiogenesis and nitric oxide signaling — building the vascular supply to a repair site. TB-500 acts through actin sequestration, influencing cell migration — getting repair cells to that site. The mechanisms are unrelated, which is why the literature studies them together.
Is TB-500 the same as Thymosin Beta-4?
It depends on the vendor. The name originally referred to a 7-amino-acid fragment (MW ~878). Most of what is sold as TB-500 is full-length Thymosin Beta-4 (43 amino acids, MW 4963) — a different molecule, more than five times the mass. CompoundPlug supplies full-length Thymosin Beta-4 and publishes the molecular weight and sequence.
Are BPC-157 and TB-500 used together in research?
Frequently. The rationale is that their mechanisms are complementary rather than overlapping — one builds vascular supply, the other moves repair cells. CompoundPlug supplies both individually and as a blend.
Which has more research behind it?
BPC-157 has the broader preclinical literature, with independent replication on tendon and bone models. Both have effectively no human clinical data.
Is either approved in Canada?
No. Neither BPC-157 nor TB-500 is an authorized health product in Canada. Neither is a controlled substance.
How does actin sequestration work?
Actin is the protein cells use to move, and it exists as free monomers (G-actin) or polymerised filaments (F-actin). To crawl toward a wound, a cell needs a large pool of free monomers to build with. Thymosin Beta-4 binds G-actin and maintains that pool — cells with more available free actin migrate faster.